Overview
Treating Tardive Dyskinesia: Clinical Challenges and Patient Perspectives
TD Clinical Commentary
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This Clinical Commentary consists of an HD video roundtable discussion with two leading expert psychiatrists in the field, who participate in a panel discussion of tardive dyskinesia (TD) as a widespread and undertreated condition in psychiatric populations, as well as the importance of evidence-based differential diagnostics, newly approved therapeutics for treatment of the condition, and strategies for both personalized and improved patient care. This activity additionally includes an interview with a leading neurologist who reviews diagnostic algorithms for TD and shares her perspective on the impact of new drug approvals and strategies for working together with psychiatrists in managing patients with TD. Throughout the activity, testimonials of a patient with tardive dyskinesia are incorporated to bring relevance to the patient perspective, experience and treatment goals.
This activity is intended for psychiatrists, neurologists, and other clinicians involved in the management of patients with TD.
Tardive dyskinesia (TD) is a medication-induced, disabling, and often-permanent neurological, hyperkinetic movement-disorder syndrome. TD has significant impact on patients’ activities of daily living (ADLs) and overall quality of life. Physicians require education and awareness on diagnostic algorithms for TD, on agents newly approved for its treatment, and on the associated risks/benefits of those agents’ use in the TD population based on the most recent clinical data and evidence.
Upon completion of this activity, participants will be able to:
• Evaluate possible clinical indication(s) and patient population(s) that may be at increased risk for tardive dyskinesia (TD).
• Discuss the role of dopamine antagonists and/or other therapies that may play a role in the pathophysiology of TD.
• Recognize the risks, benefits, and possible complications associated with managing TD in the psychiatric population.
• Describe the importance of differential diagnosis and current evidence-based treatment paradigms for patients at risk for TD.
• Interpret the clinical trial efficacy and safety data of novel and emerging therapies for TD.
• Evaluate possible clinical indication(s) and patient population(s) that may be at increased risk for tardive dyskinesia (TD).
• Discuss the role of dopamine antagonists and/or other therapies that may play a role in the pathophysiology of TD.
• Recognize the risks, benefits, and possible complications associated with managing TD in the psychiatric population.
• Describe the importance of differential diagnosis and current evidence-based treatment paradigms for patients at risk for TD.
• Interpret the clinical trial efficacy and safety data of novel and emerging therapies for TD.
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Neurocrine BioSciences.
Cynthia Comella, MD
Professor, Department of Neurological Sciences
Section of Parkinson’s Disease and Movement Disorders
Rush University Medical Center
Chicago, IL
Professor, Department of Neurological Sciences
Section of Parkinson’s Disease and Movement Disorders
Rush University Medical Center
Chicago, IL
Christoph Correll, MD
Professor, Center for Psychiatric Neuroscience,
The Feinstein Institute for Medical Research
Professor, Psychiatry and Molecular Medicine,
Hofstra Northwell School of Medicine
Medical Director, Recognition and Prevention,
Department of Psychiatry,
The Zucker Hillside Hospital
New York, NY
John Kane, MD
Professor & Chairman,
Psychiatry, Neurology and Neurosciences
Donald & Barbara Zucker School of Medicine at Hofstra/Northwell
Chairman, Department of Psychiatry
The Zucker Hillside Hospital
New York, NY
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.
The following financial relationships have been provided:
Cynthia Comella, MD
Review Panel: Neurocrine Biosciences
Christoph Correll, MD
Consultant/Advisor: Alkermes, Allergan, Angelini, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, Medavante, Merck, Neurocrine Biosciences, Otsuka, Pfizer, ROVI, Servier, Sunovion, Takeda, and Teva
Grant Support: Janssen and Teva
Shareholder: LB Pharma
Royalties: UpToDate
John Kane, MD
Consultant/Advisor: Alkermes, Allergan, Eli Lilly, Forum, Genentech, Lundbeck, Intracellular Therapies,
Merck, Janssen, Johnson & Johnson, Neurocrine Biosciences, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda, and Teva Pharmaceuticals
Grant Support: Otsuka, Lundbeck, and Janssen
Shareholder: LB Pharma and Vanguard Research Group
Patient Disclosure: No financial relationships reported
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Tetrabenazine, Clonazepam and Vitamin E for the management of tardive dyskinesia
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 65% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
For questions, contact Katlyn Cooper at kcooper@achlcme.org.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.